Molecules that bind to cd94/nkg2a heterodimer polypeptides
US-2024415889-A1 · Dec 19, 2024 · US
Anti-SEZ6 antibody drug conjugates and methods of use
US11077203B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11077203-B2 |
| Application number | US-202016908645-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 22, 2020 |
| Priority date | May 30, 2018 |
| Publication date | Aug 3, 2021 |
| Grant date | Aug 3, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided are novel anti-SEZ6 antibodies and antibody drug conjugates, and methods of using such anti-SEZ6 antibodies and antibody drug conjugates to treat cancer.
First claim
Opening claim text (preview).
What is claimed is: 1. An anti-human SEZ6 antibody, comprising a heavy chain sequence of SEQ ID NO:3 and a light chain sequence of SEQ ID NO:4. 2. The antibody of claim 1 wherein the antibody is conjugated to a calicheamicin payload. 3. The antibody of claim 2 wherein the calicheamicin payload comprises N-Ac calicheamicin. 4. A SEZ6 antibody drug conjugate (ADC) having the structure of ADC1: wherein Ab comprises an anti-human SEZ6 antibody having a heavy chain sequence of SEQ ID NO:3 and a light chain sequence of SEQ ID NO:4, and n is 2.
Assignees
Inventors
Classifications
- A61K47/68Primary
the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment · CPC title
against receptors, cell surface antigens or cell surface determinants · CPC title
- C07K16/18Primary
against material from animals or humans · CPC title
Antineoplastic agents · CPC title
the tumour determinant being from lung cancer cell · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11077203B2 cover?
- Provided are novel anti-SEZ6 antibodies and antibody drug conjugates, and methods of using such anti-SEZ6 antibodies and antibody drug conjugates to treat cancer.
- Who is the assignee on this patent?
- Abbvie Stemcentrx Llc
- What technology area does this patent fall under?
- Primary CPC classification A61K47/68. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).